Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Earnings Briefs: Biogen, Celgene, Actelion, Cubist

Executive Summary

Biogen gains approval for its latest MS treatment in the EU; Celgene pushes ahead with Otezla, despite soft launch; Actelion looking outside PAH for business development; Cubist developing patient access program for Sivextro.

You may also be interested in...



R&D News In Brief: Otezla Disappoints But Dupilumab Doesn’t, Astellas Files Antifungal And NovoSeven Adds Indication

POSTURE study will continue unchanged for Celgene’s PDE-4 inhibitor due to meaningful efficacy seen in a pre-specified subgroup with early-stage disease. Astellas submits an NDA for broad-spectrum antifungal isavuconazole in invasive aspergillosis and invasive mucormycosis. Other drug development news, in brief …

Celgene Prices Psoriatic Arthritis Drug Otezla At A Discount, But Higher Than Expected

FDA’s approval of oral apremilast paves the way for the company to establish itself in a range of inflammatory conditions.

Moving Beyond Cubicin: Cubist Sets The Stage For Long-Term Growth

Cubist has focused on marketing its sole drug, Cubicin, since the antibiotic was approved in 2003, but through business development and clinical progress, the biopharma is in the midst of a transformation.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel